Zymeworks Inc. (ZYME)
Largest Insider Buys in Sector
ZYME Stock Price History Chart
ZYME Stock Performance
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or …
Insider Activity of Zymeworks Inc.
Over the last 12 months, insiders at Zymeworks Inc. have bought $0 and sold $428,199 worth of Zymeworks Inc. stock.
On average, over the past 5 years, insiders at Zymeworks Inc. have bought $16.77M and sold $2.47M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,350,000 shares for transaction amount of $27.2M was made by EcoR1 Capital, LLC (10 percent owner) on 2023‑06‑16.
List of Insider Buy and Sell Transactions, Zymeworks Inc.
| 2024-01-08 | Sale | Chair & CEO | 5,706 0.0079% | $11.22 | $63,996 | -5.89% | ||
| 2024-01-08 | Sale | Chief Scientific Officer | 2,339 0.0033% | $11.22 | $26,233 | -5.89% | ||
| 2024-01-08 | Sale | SVP & Chief Financial Officer | 1,431 0.002% | $11.22 | $16,050 | -5.89% | ||
| 2024-01-05 | Sale | Chair & CEO | 18,198 0.0262% | $10.65 | $193,849 | +2.66% | ||
| 2024-01-05 | Sale | Chief Scientific Officer | 7,460 0.0107% | $10.65 | $79,465 | +2.66% | ||
| 2024-01-05 | Sale | SVP & Chief Financial Officer | 4,563 0.0066% | $10.65 | $48,606 | +2.66% | ||
| 2023-12-11 | Sale | SVP & Chief Financial Officer | 886 0.0013% | $9.13 | $8,089 | +16.36% | ||
| 2023-06-16 | 10 percent owner | 3.35M 5.0195% | $8.12 | $27.2M | +7.27% | |||
| 2023-03-28 | 10 percent owner | 200,000 0.2981% | $8.00 | $1.6M | +6.44% | |||
| 2023-03-10 | Sale | President & COO | 2,977 0.0044% | $7.83 | $23,298 | +6.56% | ||
| 2023-01-20 | director | 163,400 0.2428% | $9.88 | $1.62M | -16.45% | |||
| 2023-01-19 | director | 144,100 0.2124% | $9.49 | $1.37M | -13.66% | |||
| 2023-01-18 | director | 203,000 0.3051% | $10.00 | $2.03M | -16.43% | |||
| 2023-01-17 | director | 440,000 0.6486% | $9.80 | $4.31M | -16.43% | |||
| 2023-01-13 | director | 342,100 0.5024% | $9.81 | $3.35M | -16.78% | |||
| 2023-01-11 | director | 106,300 0.1527% | $7.87 | $836,911 | +1.43% | |||
| 2023-01-10 | director | 920,000 1.3565% | $7.65 | $7.04M | +7.02% | |||
| 2022-11-10 | Sale | Chief Medical Officer | 2,475 0.0037% | $8.10 | $20,045 | -2.32% | ||
| 2022-10-13 | 10 percent owner | 30,481 0.0481% | $5.03 | $153,435 | +63.80% | |||
| 2022-03-10 | Sale | Chief Operating Officer | 2,979 0.0048% | $6.88 | $20,496 | -6.14% |
Insider Historical Profitability
| EcoR1 Capital, LLC | 10 percent owner | 13437473 19.5092% | $14.14 | 9 | 0 | <0.0001% |
| Redmile Group, LLC | 10 percent owner | 6075918 8.8213% | $14.14 | 1 | 0 | +63.8% |
| Tehrani Ali | Chief Executive Officer | 260325 0.378% | $14.14 | 1 | 6 | +12.44% |
| Josephson Neil | Chief Medical Officer | 14449 0.021% | $14.14 | 1 | 1 | <0.0001% |
| Cox Troy | director | 7500 0.0109% | $14.14 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Ecor1 Capital Llc | $141.36M | 19.01 | 13.44M | 0% | +$0 | 0.99 | |
| Bvf Inc Il | $61.75M | 8.3 | 5.87M | 0% | +$0 | 0.45 | |
| Redmile Group | $58.5M | 7.87 | 5.56M | -3.96% | -$2.41M | 0.6 | |
| Morgan Stanley | $53.77M | 7.23 | 5.11M | +5.14% | +$2.63M | <0.01 | |
| BlackRock | $43.09M | 5.79 | 4.1M | +4.39% | +$1.81M | <0.01 |